SCHEMBL2633190

SCHEMBL2633190

CCCCOCCC(C#N)c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.39
ALDH1A1 P00352 3/20 0.39
HPGD P15428 1/20 0.38
LTA4H P09960 2/20 0.38
PBRM1 Q86U86 1/20 0.37
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36
RECQL P46063 1/20 0.36
CCR1 P32246 1/20 0.35
TRPA1 O75762 1/20 0.34
HTR2A P28223 1/20 0.34
HRH1 P35367 1/20 0.34
CTSL P07711 1/20 0.34
CTSS P25774 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1445763 0.83 CCR1 (0.42) TSHRALDH1A1HPGDKDM4EMAPT
SCHEMBL2633138 0.83 OPRM1 (0.36) MAPTKMT2A
SCHEMBL2465427 0.82 CCR1 (0.40) TSHRALDH1A1PBRM1MEN1KMT2A
SCHEMBL1310360 0.82 CCR1 (0.41) TSHRALDH1A1KDM4EMAPTCCR1
SCHEMBL28686925 0.80 HTR2A (0.41) TSHRALDH1A1CCR1TRPA1HTR2A
SCHEMBL7309655 0.80 HTR2A (0.41) TSHRALDH1A1CCR1TRPA1HTR2A
SCHEMBL28978060 0.80 HTR2A (0.41) TSHRALDH1A1CCR1TRPA1HTR2A
SCHEMBL7754790 0.80 HTR2A (0.41) TSHRALDH1A1CCR1TRPA1HTR2A
SCHEMBL953748 0.79 TRPA1 (0.43) TSHRALDH1A1HPGDPBRM1MEN1
SCHEMBL1554435 0.78 PBRM1 (0.41) TSHRALDH1A1HPGDPBRM1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8357809-B2 Acyclic IKur inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-22 US disclosed
US-20120094983-A1 ACYCLIC IKUR INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-04-19 US disclosed
US-7915410-B2 Acyclic IKur inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-03-29 US disclosed
US-20070082909-A1 Acyclic Ikur inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-04-12 US disclosed
WO-2007030582-A2 ACYCLIC IKUR INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070082909-A1 Acyclic Ikur inhibitors KCNH2, KCNJ2, KCNH3 TSHR 566/4885ALDH1A1 1792/4885HPGD 2919/4885
US-20120094983-A1 ACYCLIC IKUR INHIBITORS KCNH2, KCNJ2, KCNH3 TSHR 566/4885ALDH1A1 1792/4885HPGD 2919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.